Literature DB >> 22136980

Solving the antidepressant efficacy question: effect sizes in major depressive disorder.

Paul A Vöhringer1, S Nassir Ghaemi.   

Abstract

BACKGROUND: Numerous reviews and meta-analyses of the antidepressant literature in major depressive disorders (MDD), both acute and maintenance, have been published, some claiming that antidepressants are mostly ineffective and others that they are mostly effective, in either acute or maintenance treatment.
OBJECTIVE: The aims of this study were to review and critique the latest and most notable antidepressant MDD studies and to conduct our own reanalysis of the US Food and Drug Administration database studies specifically analyzed by Kirsch et al.
METHODS: We gathered effect estimates of each MDD study. In our reanalysis of the acute depression studies, we corrected analyses for a statistical floor effect so that relative (instead of absolute) effect size differences were calculated. We also critiqued a recent meta-analysis of the maintenance treatment literature.
RESULTS: Our reanalysis showed that antidepressant benefit is seen not only in severe depression but also in moderate depression and confirmed a lack of benefit for antidepressants over placebo in mild depression. Relative antidepressant versus placebo benefit increased linearly from 5% in mild depression to 12% in moderate depression to 16% in severe depression. The claim that antidepressants are completely ineffective, or even harmful, in maintenance treatment studies involves unawareness of the enriched design effect, which, in that analysis, was used to analyze placebo efficacy. The same problem exists for the standard interpretation of those studies, although they do not prove antidepressant efficacy either, since they are biased in favor of antidepressants.
CONCLUSIONS: In sum, we conclude that antidepressants are effective in acute depressive episodes that are moderate to severe but are not effective in mild depression. Except for the mildest depressive episodes, correction for the statistical floor effect proves that antidepressants are effective acutely. These considerations only apply to acute depression, however. For maintenance, the long-term efficacy of antidepressants is unproven, but the data do not support the conclusion that they are harmful.
Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136980      PMCID: PMC3242920          DOI: 10.1016/j.clinthera.2011.11.019

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  19 in total

Review 1.  Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers?

Authors:  Frederick K Goodwin; Elizabeth A Whitham; S Nassir Ghaemi
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

2.  Three-year outcomes for maintenance therapies in recurrent depression.

Authors:  E Frank; D J Kupfer; J M Perel; C Cornes; D B Jarrett; A G Mallinger; M E Thase; A B McEachran; V J Grochocinski
Journal:  Arch Gen Psychiatry       Date:  1990-12

3.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

Review 4.  SSRIs versus other antidepressants for depressive disorder.

Authors:  J R Geddes; N Freemantle; J Mason; M P Eccles; J Boynton
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 6.  Risk of recurrence following discontinuation of lithium treatment in bipolar disorder.

Authors:  T Suppes; R J Baldessarini; G L Faedda; M Tohen
Journal:  Arch Gen Psychiatry       Date:  1991-12

7.  The Carroll rating scale for depression. III. Comparison with other rating instruments.

Authors:  M Feinberg; B J Carroll; P E Smouse; S G Rawson
Journal:  Br J Psychiatry       Date:  1981-03       Impact factor: 9.319

8.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

9.  Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.

Authors:  James H Kocsis; Michael E Thase; Madhukar H Trivedi; Richard C Shelton; Susan G Kornstein; Charles B Nemeroff; Edward S Friedman; Alan J Gelenberg; David L Dunner; Robert M A Hirschfeld; Anthony J Rothschild; James M Ferguson; Alan F Schatzberg; John M Zajecka; Ronald D Pedersen; Bing Yan; Saeed Ahmed; Jeff Musgnung; Philip T Ninan; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2007-07       Impact factor: 4.384

10.  Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity.

Authors:  Andreas B Schmitt; Michael Bauer; Hans-Peter Volz; Hans-Jürgen Moeller; Qin Jiang; Philip T Ninan; Peter-Andreas Loeschmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-03-03       Impact factor: 5.270

View more
  13 in total

1.  US trends in quality-adjusted life expectancy from 1987 to 2008: combining national surveys to more broadly track the health of the nation.

Authors:  Susan T Stewart; David M Cutler; Allison B Rosen
Journal:  Am J Public Health       Date:  2013-09-12       Impact factor: 9.308

2.  Genetic biomarkers of placebo response: what could it mean for future trial design?

Authors:  Kathryn T Hall; Ted J Kaptchuk
Journal:  Clin Investig (Lond)       Date:  2013-04-01

Review 3.  A systematic approach to pharmacotherapy for geriatric major depression.

Authors:  Benoit H Mulsant; Daniel M Blumberger; Zahinoor Ismail; Kiran Rabheru; Mark J Rapoport
Journal:  Clin Geriatr Med       Date:  2014-06-14       Impact factor: 3.076

4.  GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis.

Authors:  Daniel M Kawaguchi; Stephen J Glatt
Journal:  Pharmacogenomics       Date:  2014-08       Impact factor: 2.533

5.  Antidepressants are not overprescribed for mild depression.

Authors:  Gregory E Simon; Rebecca C Rossom; Arne Beck; Beth E Waitzfelder; Karen J Coleman; Christine Stewart; Belinda Operskalski; Robert B Penfold; Susan M Shortreed
Journal:  J Clin Psychiatry       Date:  2015-12       Impact factor: 4.384

6.  An HDAC-dependent epigenetic mechanism that enhances the efficacy of the antidepressant drug fluoxetine.

Authors:  C Schmauss
Journal:  Sci Rep       Date:  2015-02-02       Impact factor: 4.379

7.  Differential co-expression and regulation analyses reveal different mechanisms underlying major depressive disorder and subsyndromal symptomatic depression.

Authors:  Fan Xu; Jing Yang; Jin Chen; Qingyuan Wu; Wei Gong; Jianguo Zhang; Weihua Shao; Jun Mu; Deyu Yang; Yongtao Yang; Zhiwei Li; Peng Xie
Journal:  BMC Bioinformatics       Date:  2015-04-03       Impact factor: 3.169

Review 8.  The genetics of major depression.

Authors:  Jonathan Flint; Kenneth S Kendler
Journal:  Neuron       Date:  2014-02-05       Impact factor: 17.173

9.  Antidepressants: relationship to the time to psychiatric readmission and probability of being in hospital in depressive patients.

Authors:  Ingeborg Warnke; Carlos Nordt; Jörn Moock; Wolfram Kawohl; Wulf Rössler
Journal:  Front Public Health       Date:  2014-05-08

10.  A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression.

Authors:  Amy R Romijn; Julia J Rucklidge; Roeline G Kuijer; Chris Frampton
Journal:  Aust N Z J Psychiatry       Date:  2017-01-10       Impact factor: 5.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.